<DOC>
	<DOCNO>NCT01978236</DOCNO>
	<brief_summary>This global , multi-centre , open-label , study GSK2118436 conduct 30 evaluable subject resectable , BRAF V600E V600K mutation-positive metastatic melanoma brain . All subject study require accessible extracranial metastasis agreeable undergo repetitive biopsy . The first cohort 15 subject receive dabrafenib orally 150mg twice daily ( BID ) 7 14 day prior surgery ( Cohort A ) ; second cohort 15 subject receive combination dabrafenib 150 mg BID trametinib 2 mg daily 7 14 day prior surgery ( Cohort B ) . The primary purpose study determine level distribution dabrafenib , metabolite , trametinib ( Cohort B ) parenchymal brain metastasis , extracranial metastasis , peripheral blood ( plasma ) within two cohort subject BRAF V600E/K mutation-positive melanoma metastasize brain . All subject follow survival new anti-cancer therapy total two year death subject wish withdraw follow-up .</brief_summary>
	<brief_title>Dabrafenib/Trametinib , BRAF BRAF AND MEK Pre-op With BRAF MEK Post-op , Phase IIB , Melanoma With Brain Mets , Biomarkers Metabolites</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Signed write informed consent Histologicallyconfirmed metastatic melanoma ( Stage IV ) , carry BRAF V600E V600K mutation determine test certified clinical diagnostic purpose . Previously perform certified BRAF test acceptable . If prior BRAF mutation test result available , test distant metastasis prefer , test regional metastasis primary tumor also acceptable At least one intracranial lesion &gt; =1.0 cm &lt; =4.0 cm treat surgical resection opinion treat physician , immediate local therapy clinically indicate At least two extracranial lesion easily accessible biopsy , judgment treat physician . Easily accessible tumor may include cutaneous , subcutaneous , superficial lymph node metastasis . Age &gt; 18 year age . Able swallow retain oral medication Women childbearing potential must willing practice acceptable method birth control study Women childbearing potential must negative serum pregnancy test within 14 day first dose study treatment . Must able understand comply protocol requirement instruction Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Must adequate organ function define follow screen value ( Retesting borderline screen organ function treatment blood transfusion , growth factor etc . allow ) : Absolute neutrophil count ( ANC ) &gt; =1.2x10^9/L Hemoglobin &gt; =9 g/dL Platelets &gt; =100x10^9/L Serum bilirubin &lt; =1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; =2.5xULN Serum creatinine &lt; =1.5 mg/dL ( If serum creatinine &gt; 1.5 mg/dL , calculate creatinine clearance use standard Cockcroft Gault Method Creatinine clearance must &gt; 50 mL/min ) Prothrombin time ( PT ) /International normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; =1.3xULN Left ventricular ejection fraction ( LVEF ) &gt; = institutional low limit normal ( LLN ) Neurological symptom related brain metastasis control stable decreasing dose oral steroid least 7 day prior start GSK2118436 Prior Central Nervous System ( CNS ) direct local therapy , include surgical resection , whole brain radiation ( WBRT ) , Stereotactic radiosurgery ( SRS ) , gamma knife ( GK ) Previous treatment BRAF MEK inhibitor Cancer therapy ( chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , major surgery ) investigational anticancer drug within last 3 week , chemotherapy without delayed toxicity within last 2 week , precede first dose study treatment . Current expect use prohibit medication , include enzymeinducing antiepileptic drug ( EIAEDs ) treatment GSK2118436 . Presence leptomeningeal disease dural metastasis . History another active malignancy within past 5 year , malignancy confirm activate RAS mutation . The prospective RAS mutation testing require , however , result previous RAS test know , must use assess eligibility . Subjects history completely resect nonmelanoma skin cancer eligible . Known allergy contrast agent require magnetic resonance imaging ( MRI ) intracranial lesion , contraindication MRI , i.e. , pacemaker Current use therapeutic warfarin . Lowmolecularweight heparin prophylactic lowdose warfarin permit Unresolved toxicity National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( CTCAE v4.0 ) Grade 2 high previous anticancer therapy , except alopecia Presence active gastrointestinal disease condition interfere significantly absorption drug . History prior symptomatic stroke , dementia , significant central neurologic condition ( i.e . multiple sclerosis ) A history know Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection Current acute infection require intravenous antibiotic A history know glucose6phosphate dehydrogenase ( G6PD ) deficiency The history evidence follow cardiac abnormality : Corrected QT ( QTc ) interval use Bazett 's Formula ; ( QTcB ) &gt; = 480 msec A history acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization Coronary angioplasty stenting within past 12 week Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system Abnormal cardiac valve morphology ( &gt; = Grade 2 ) document echocardiogram ( ECHO ) History evidence clinically significant uncontrolled cardiac arrhythmia Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mm Hg control antihypertensive therapy Subjects intracardiac defibrillator permanent pacemaker Pregnant , lactate breastfeed female Any serious and/or unstable preexist medical , psychiatric disorder condition could interfere subject 's safety , obtain informed consent compliance study procedure Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate GSK2118436 excipients contraindicate participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>BRAF V600E mutation</keyword>
	<keyword>brain metastasis</keyword>
	<keyword>BRAF V600K mutation</keyword>
	<keyword>Metastatic melanoma</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>brain neoplasm</keyword>
	<keyword>GSK2118436</keyword>
</DOC>